Our multidisciplinary panel of experts with diverse perspectives and insights will discuss the FDA’s recent decision to remove the boxed warning from menopause hormone therapy. The conversation will review the scientific evidence behind this regulatory change, its impact on patient care and safety communication, and the evolving understanding of hormone therapy. The session will also consider implications for clinical practice, shared decision-making, and the broader conversation around women’s midlife health.

Lisa Larkin, MD - Lisa Chacko, MD - Amy Comander, MD - Shari Goldfarb, MD - Steven Goldstein, MD - Jen Gunter, MD - Risa Kagan, MD - Jewel Kling, MD - Jennifer Lanoff, WHNP-BC - Jill Liss, MD - Maryam Lustberg, MD - Pauline Maki, PhD - Corrinne Menn, MD - Dawn Mussallem, DO - Genevieve Neal-Perry, MD, PhD - Sharon Parish, MD - Rachel Pope, MD - Lauren Streicher, MD - Rebecca Thurston, PhD

Don’t miss this timely and informative discussion for clinicians, educators, and anyone interested in evidence-based women’s health.